Burning Rock Biotech Limited (BNR)

CN — Healthcare Sector
Peers: FONR  SERA  OLK  LMDX  STIM  DRIO  GTH  SHC  NEOG  QGEN  SYNH  PSNL  CDNA 

Automate Your Wheel Strategy on BNR

With Tiblio's Option Bot, you can configure your own wheel strategy including BNR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BNR
  • Rev/Share 4.9905
  • Book/Share 5.6194
  • PB 0.4053
  • Debt/Equity 0.0901
  • CurrentRatio 2.9163
  • ROIC -0.5652

 

  • MktCap 24522469.665
  • FreeCF/Share -0.9504
  • PFCF -0.2496
  • PE -0.6792
  • Debt/Assets 0.0591
  • DivYield 0
  • ROE -0.5285

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
BNR
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application …

Read More
image for news Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

About Burning Rock Biotech Limited (BNR)

  • IPO Date 2020-06-12
  • Website https://www.brbiotech.com
  • Industry Medical - Diagnostics & Research
  • CEO Mr. Yusheng Han
  • Employees 674
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.